|
|
|
Cancer Genetics Inc 
|
3.5 -0.41 (-0.1%) |
01-27 16:00 |
Open: |
3.8 |
Pre close: |
3.91 |
Target:
|
5.44
|
High: |
3.933 |
Low: |
3.49 |
Resistance:
|
4.66
5.95
|
Volume: |
405,741 |
Market Cap: |
14M |
Support:
|
2.56
2.13
|
|
|
|
Technical Analysis |
Moving Averages |
MA(5):
|
3.98
 |
MACD |
MACD(12,26):
|
0.33  |
MA(20): |
3.45  |
Signal(12,26,9): |
0.31  |
MA(100): |
3.34  |
Stochastic Oscillator |
%K(14,3):
|
30.37  |
MA(250): |
3.37  |
%D(3): |
38.09  |
Average Volume(K) |
3-Month: |
71406
|
52-Week |
High:
|
10.39 |
10-Days: |
129949 |
Low: |
1.92 |
RSI |
RSI(14):
|
50.95  |
Change(%): |
-15.9 |
Financials, Statistics and Valuation |
EPS |
-2.071 |
Return on Equity (ttm) |
-68.7 |
Shares Out. (M) |
4.09 |
EPS Est. Current Year |
-0.860 |
Return on Assets (ttm) |
-14.9 |
Shares Float (M) |
3.51 |
EPS Est. Next Year |
-0.260 |
PEG Ratio |
0.00 |
% Held by Insiders |
7.49 |
EPS Est. Next Quarter |
-0.100 |
Qtrly Rev. Growth |
-24.2 |
% Held by Institutions |
16.92 |
Forward EPS |
-0.750 |
Gross Profit (p.s.) |
0.880 |
Shares Short (K) |
29 |
Book Value (p.s.) |
1.920 |
EBITDA (p.s.) |
-0.719 |
P/E |
-1.69 |
Sales Per Share |
1.548 |
Qtrly Earnings Growth |
0.00 |
P/BV |
1.82 |
Profit Margin |
-71.50 |
Operating Cash Flow
(M) |
-6.09 |
P/S |
2.26 |
Operating Margin |
-57.50 |
Levered Free Cash Flow
(M) |
3.40 |
P/CF |
-2.35 |
|
|
|
|
|